Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Karen Cichowski Clear advanced filters

  • Inhibitors of RAF enzymes can suppress or activate the same signalling pathway. The details of how this happens provide a cautionary note for those targeting the pathway for anticancer drug discovery.

    • Karen Cichowski
    • Pasi A. Jänne
    News & Views
    Nature
    Volume: 464, P: 358-359

  • AKT inhibitors synergize with agents that suppress the histone methyltransferase EZH2 and promote robust tumour regression in multiple triple-negative breast cancer models in vivo by triggering an involution-like process.

    • Amy E. Schade
    • Naiara Perurena
    • Karen Cichowski
    ResearchOpen Access
    Nature
    Volume: 635, P: 755-763

  • In this Review, Cichowski and colleagues provide an overview of combinatorial strategies designed to treat RAS-driven cancers that are based on four concepts that include vertical pathway inhibition, co-targeting RAS and adaptive survival pathways, co-targeting downstream or converging pathways and capitalizing on other cancer-associated vulnerabilities.

    • Naiara Perurena
    • Lisa Situ
    • Karen Cichowski
    Reviews
    Nature Reviews Cancer
    Volume: 24, P: 316-337

  • A new study identifies SPRY4 as a tumor suppressor in acute myeloid leukemia and shows that loss of SPRY4 acts as an alternative mechanism to drive RAS signaling. In addition, a paradigm of cooperativity in which combined loss of multiple negative regulators of the RAS pathway supplants the need for RAS mutations is suggested.

    • Rebecca Lock
    • Karen Cichowski
    News & Views
    Nature Genetics
    Volume: 47, P: 426-427

  • Metastasis is a fatal complication of prostate cancer, but its mechanisms remain largely unknown. In this report, the authors identify a signaling pathway commonly deregulated in human prostate cancer and describe how it can foster both primary growth and metastatic tumor progression. Epigenetic silencing of the RasGAP DAB2IP by EZH2 overexpression results in aberrant activation of Ras signaling, but also of NF-κB. These two events are mediated by different DAB2IP domains and have distinct roles in localized growth and distant dissemination.

    • Junxia Min
    • Alexander Zaslavsky
    • Karen Cichowski
    Research
    Nature Medicine
    Volume: 16, P: 286-294